GlassScriptPhysician profile
Nagarjuna Yerra
NPI 1275542649
$664.59
in general payments reported to CMS, 2019-2025
17 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $36.87 · 2021: $52.31 · 2022: $39.30 · 2023: $116 · 2024: $76.06 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $176.39 | 2019 | |
| Abbvie INC. | $98.00 | 2021-2025 | Linzess, Viberzi |
| Braintree Laboratories, INC. | $73.84 | 2019-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $39.96 | 2025 | Voquezna |
| Boston Scientific Corporation | $34.80 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.55 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.47 | 2021-2024 | Dificid |
| Mauna Kea Technologies, INC. | $24.57 | 2022 | |
| Madrigal Pharmaceuticals | $24.37 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $23.01 | 2019 | |
| Abbott Laboratories | $17.17 | 2025 | Alere Triage |
| Capsovision, INC. | $16.68 | 2023 | Capsocam Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $16.46 | 2023 | Entyvio |
| Genzyme Corporation | $15.67 | 2023 | |
| Medtronic, INC. | $15.07 | 2023 | Gi Genius |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $14.73 | 2022 | |
| Ardelyx, INC. | $13.85 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagarjuna Yerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.